The group’s principal activities include acquiring and developing novel, small molecule therapeutics. Specific customers of the group include Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Pharma Corporation and Meiji Seika Kaisha, Ltd. The products of the group include inhaled corticosteroids, bronchodilators and leukotriene antagonists. The group products sold under the trade names Flovent(R), Vanceril(R) and Singulair(R). The group operates from the United States. The revenue of the group for the year 2006 was $263,877.
